Therapeutic inhibition of EZH2 in SHH-MB cells promotes tumor cell differentiation, impairs tumor growth and proliferation, and reduces stemness, suggesting that EZH2 represents a promising druggable target, which shows significantly reduced proliferation and impaired self-renewal in response to EZH2 inhibition (196–198). Here, EZH2 is linked to neoplasm.